VOGLIZOME M0.2

Composition:

• Active Ingredients:

  • Voglibose: 0.3 mg

  • Metformin Hydrochloride: 500 mg

Formulation:

• Form: Tablet

• Dosage Strengths:

  • Voglibose 0.3 mg + Metformin Hydrochloride 500 mg

• Route of Administration: Oral

Status:

• Prescription Status: Prescription-only medication (Rx)

• Regulatory Approval: Approved by drug regulatory authorities (such as the FDA or equivalent) for the management of type 2 diabetes mellitus.

Benefits:

• Enhanced Blood Sugar Control:

  • Voglibose: An alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates, helping to reduce postprandial (after meal) blood glucose spikes.

  • Metformin Hydrochloride: A biguanide that decreases glucose production in the liver, improves insulin sensitivity, and enhances peripheral glucose uptake. The combination helps in better overall glycemic control.

• Dual Mechanism of Action: The combination of Voglibose and Metformin addresses different aspects of glucose metabolism, making it effective for managing type 2 diabetes, especially in patients with elevated postprandial glucose levels.

• Reduced Postprandial Glucose Peaks: Effective in controlling spikes in blood glucose levels that occur after meals, which can contribute to better long-term diabetes management and reduced risk of complications.

• Complementary Therapy: The combination can be used in conjunction with other antidiabetic agents to achieve optimal blood glucose control and improve patient outcomes.